Joint bleeds with significant limitation in ROM at presentation needed more time to recover. Patients with severe haemophilia on emicizumab showed shorter recovery after joint bleeding. Follow-up should be personalized and extended beyond one month.
Aertssen et al. (Sat,) studied this question.